Peter Thompson Sells 875 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 875 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $44.49, for a total value of $38,928.75. Following the completion of the transaction, the director owned 3,595,011 shares of the company’s stock, valued at approximately $159,942,039.39. This trade represents a 0.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Sionna Therapeutics Stock Performance

Shares of SION stock traded down $1.84 during mid-day trading on Friday, reaching $42.37. 1,954,673 shares of the company’s stock traded hands, compared to its average volume of 270,007. Sionna Therapeutics, Inc. has a 12 month low of $7.26 and a 12 month high of $45.00. The company’s 50-day moving average price is $38.54 and its 200-day moving average price is $27.05.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.06.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on SION shares. BTIG Research started coverage on shares of Sionna Therapeutics in a report on Wednesday, November 19th. They set a “buy” rating and a $50.00 target price for the company. Raymond James Financial reissued a “strong-buy” rating on shares of Sionna Therapeutics in a report on Wednesday, November 5th. Wall Street Zen upgraded Sionna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Jones Trading started coverage on Sionna Therapeutics in a research report on Monday, September 8th. They issued a “buy” rating and a $46.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $40.33.

Hedge Funds Weigh In On Sionna Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. RA Capital Management L.P. purchased a new stake in shares of Sionna Therapeutics during the 1st quarter valued at about $109,258,000. TPG GP A LLC bought a new position in Sionna Therapeutics during the first quarter valued at approximately $69,925,000. Atlas Venture Life Science Advisors LLC purchased a new stake in Sionna Therapeutics in the first quarter worth approximately $38,639,000. Viking Global Investors LP grew its position in Sionna Therapeutics by 8.2% in the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock worth $55,436,000 after purchasing an additional 242,427 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in Sionna Therapeutics by 2.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,221,188 shares of the company’s stock valued at $38,538,000 after buying an additional 51,589 shares during the last quarter.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.